Destiny unveils new antibacterial drug

UK-based pharmaceutical company Destiny Pharma presented research into the rapid antibacterial activity of its latest platform of drugs against  Staphylococcus aureus at the European Congress of Clinical Microbiology  and Infectious Diseases, held in Helsinki, Finland. While the company's  lead antimicrobial XF-73 continues on course within Phase I/IIa clinical  development, Destiny has now demonstrated the novel ant-bacterial  mechanism of action of DPD-207. This is an example of its new platform  of metallo-porphyrin drugs which has been proven to act in a similar  manner to the XF drug platform.

The XF drugs: kill bacteria extremely quickly (much faster than  traditional antibiotics); bacteria such as methicillin-resistant  Staphylococcus aureus seem unable to become resistant to XF/MP drug  action (unlike many antibiotics to which the superbug can rapidly become  resistant); and kill bacteria within biofilms (the protective jelly  bacteria produce around themselves, which acts as a protective barrier  against antibiotics).

The MP drugs appear to share many of the same revolutionary and highly  advantageous anti-bacterial properties of the XF drugs, the company  claims.